Evidence map›Paper›PMID 41527361›Full record

ArticleThe Journal of clinical endocrinology and metabolism2026

MASLD coexisting with PCOS increases cardiometabolic risk.

Oyekoya T Ayonrinde, Trevor A Mori, Leon A Adams, Lawrence J Beilin, John K Olynyk, Roger Hart

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oyekoya T AyonrindeMedical School, The University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0002-0598-151X
Trevor A MoriMedical School, The University of Western Australia, Nedlands, WA 6009, Australia.
Leon A AdamsMedical School, The University of Western Australia, Nedlands, WA 6009, Australia.
Lawrence J BeilinMedical School, The University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0003-4853-7360
John K OlynykDepartment of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA 6150, Australia.
Roger HartMedical School, The University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0002-6610-3040

Funding

Curtin UniversityFremantle HospitalFuture Health Research and Innovation FundGastroenterological Society of AustraliaHeart FoundationLions Eye InstituteNational Health and Medical Research Council 003209National Health and Medical Research Council 1102106National Health and Medical Research Council 1109057National Health and Medical Research Council 211912National Health and Medical Research Council 353514National Health and Medical Research Council 403968National Health and Medical Research Council 403981National Health and Medical Research Council 634445National Heart Foundation 1147677Royal Perth Hospital Medical Research FoundationSpinnaker Health Research FoundationUniversity of Western AustraliaWA BranchWellcome Trust 102301
6 · The paper itself

Abstract

BACKGROUND AND

aimsIn women in their reproductive years, metabolic dysfunction-associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) are the most common chronic liver and endocrine disorders, respectively. MASLD and PCOS are associated with longer-term risk of cardiometabolic complications. We aimed to determine whether PCOS coexisting with MASLD (PCOS + MASLD) predicts greater risk of future cardiometabolic adverse parameters than either condition alone after 10 years in a longitudinal study of adolescents in the Raine Study.

methodA total of 199 community-based female adolescents participating in the Raine Study had assessments for both PCOS and MASLD, including anthropometry, blood tests, and pelvic and abdominal ultrasound. Using updated diagnostic criteria, diagnoses of PCOS at age 14 years and MASLD at age 17 years, were retrospectively determined. At age 27 years, 148 participants had further anthropometry and cardiovascular and fasting blood assessments.

resultsAt age 17 years, 37 (18.6%) had MASLD, 32 (16.1%) had PCOS, 20 (10.1%) had PCOS without MASLD, and 142 (71.4%) had neither. Among adolescents with PCOS, 12/32 (37.5%) had PCOS + MASLD, associated with obesity, higher serum remnant lipoprotein cholesterol, and free and total testosterone, but lower SHBG, compared with those with only MASLD, PCOS, or neither (P < .05 for all). By age 27 years, those with PCOS + MASLD (10/148) during adolescence were more insulin resistant and had higher serum remnant lipoprotein cholesterol and triglyceride/high-density lipoprotein cholesterol ratio (P < .05 for all), compared with those with only PCOS or MASLD or neither. PCOS without MASLD or obesity in adolescence did not predict future insulin resistance.

conclusionPCOS + MASLD in adolescents, but not PCOS alone, increases the likelihood of obesity, insulin resistance and an adverse cardiometabolic phenotype during adulthood.

Indexed as

Cardiovascular DiseasesPolycystic Ovary SyndromeAdolescentAdultCardiometabolic Risk FactorsFemaleHumansInsulin ResistanceLongitudinal StudiesObesityRetrospective StudiesYoung Adultinsulin resistancemetabolic dysfunction-associated steatotic liver diseaseobesitypolycystic ovary syndromeRaine studytestosterone

Identifiers

PMID41527361
PMCPMC13183437

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.